Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec:5:100056.
doi: 10.1016/j.lanwpc.2020.100056. Epub 2020 Nov 20.

The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55)

Daniel Zl Chan  1   2 , Ralph Ah Stewart  1 , Andrew J Kerr  2   3 , Bridget Dicker  4   5 , Campbell V Kyle  6   7 , Philip D Adamson  8   9 , Gerry Devlin  10 , John Edmond  11 , Seif El-Jack  12 , John M Elliott  13   14 , Nick Fisher  15 , Charmaine Flynn  16   17 , Mildred Lee  2 , Yi-Wen Becky Liao  2 , Maxine Rhodes  16 , Tony Scott  1 , Tony Smith  4 , Martin K Stiles  18 , Andrew H Swain  5   19 , Verity F Todd  4   5 , Mark Wi Webster  1 , Michael Ja Williams  20 , Harvey D White  1 , Jithendra B Somaratne  1
Affiliations

The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55)

Daniel Zl Chan et al. Lancet Reg Health West Pac. 2020 Dec.

Abstract

Background: Countries with a high incidence of coronavirus 2019 (COVID-19) reported reduced hospitalisations for acute coronary syndromes (ACS) during the pandemic. This study describes the impact of a nationwide lockdown on ACS hospitalisations in New Zealand (NZ), a country with a low incidence of COVID-19.

Methods: All patients admitted to a NZ Hospital with ACS who underwent coronary angiography in the All NZ ACS Quality Improvement registry during the lockdown (23 March - 26 April 2020) were compared with equivalent weeks in 2015-2019. Ambulance attendances and regional community troponin-I testing were compared for lockdown and non-lockdown (1 July 2019 to 16 February 2020) periods.

Findings: Hospitalisation for ACS was lower during the 5-week lockdown (105 vs. 146 per-week, rate ratio 0•72 [95% CI 0•61-0•83], p = 0.003). This was explained by fewer admissions for non-ST-segment elevation ACS (NSTE-ACS; p = 0•002) but not ST-segment elevation myocardial infarction (STEMI; p = 0•31). Patient characteristics and in-hospital mortality were similar. For STEMI, door-to-balloon times were similar (70 vs. 72 min, p = 0•52). For NSTE-ACS, there was an increase in percutaneous revascularisation (59% vs. 49%, p<0•001) and reduction in surgical revascularisation (9% vs. 15%, p = 0•005). There were fewer ambulance attendances for cardiac arrests (98 vs. 110 per-week, p = 0•04) but no difference for suspected ACS (408 vs. 420 per-week, p = 0•44). Community troponin testing was lower throughout the lockdown (182 vs. 394 per-week, p<0•001).

Interpretation: Despite the low incidence of COVID-19, there was a nationwide decrease in ACS hospitalisations during the lockdown. These findings have important implications for future pandemic planning.

Funding: The ANZACS-QI registry receives funding from the New Zealand Ministry of Health.

Keywords: Acute coronary syndrome; Coronavirus 2019.

PubMed Disclaimer

Conflict of interest statement

DZC is supported by the A.H. Couch Research Fellowship. PDA is supported by a Heart Foundation of New Zealand Senior Fellowship (1844). YBL is supported by the Middlemore Cardiac Trust. HDW has received grant support paid to the institution and fees for serving on Steering Committees of the ODYSSEY trial from Sanofi and Regeneron Pharmaceuticals, of the STRENGTH trial from Omthera Pharmaceuticals, and of the HEART-FID study from American Regent, of the CAMELLIA study from Eisai Inc., of the DAL-GENE study from DalCor Pharma UK Inc., of the AEGIS-II study from CSL Behring, of the SCORED and SOLOIST-WHF trials from Sanofi Australia Pty Ltd., and of the CLEAR OUTCOMES study from Esperion Therapeutics Inc., and of the ACCELERATE study from Eli Lilly and Company. He has been on an Advisory Board for Genentech, Inc. San Francisco. He has received interview fees paid at ACC2018 Cardiovascular Forum by AstraZeneca.

Figures

Fig. 1
Fig. 1
Changes in event rates during the lockdown compared to non-lockdown period ACS = acute coronary syndrome; CI = confidence interval; hsTroponin = high-sensitivity Troponin; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; STEMI = ST-segment elevation myocardial infarction; SD = standard deviation; ULN = upper limit of normal p-value calculated using Mann-Whitney U test.
Fig. 2
Fig. 2
Hospitalisations for acute coronary syndrome by week. a) All acute coronary syndromes. b) ST-segment elevation myocardial infarction. c) Non-ST-segment elevation acute coronary syndromes.
Fig. 3
Fig. 3
Out-of-hospital healthcare encounters for suspected acute coronary syndromes by week. a) Ambulance attendances for suspected acute coronary syndrome. b) Community troponin I testing.
See this image and copyright information in PMC

References

    1. Lau H., Khosrawipour V., Kocbach P., Mikolajczyk A., Schubert J., Bania J. The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. J Travel Med. 2020;27(3) - PMC - PubMed
    1. Tobias A. Evaluation of the lockdowns for the SARS-CoV-2 epidemic in Italy and Spain after one month follow up. Sci Total Environ. 2020;725 - PMC - PubMed
    1. Cousins S. New Zealand eliminates COVID-19. Lancet. 2020;395(10235):1474. - PMC - PubMed
    1. Roser M., Ritchie H., Ortiz-Ospina E., Hasell J. Coronavirus pandemic (COVID-19) 2020 [27th April 2020]. Available from: https://ourworldindata.org/coronavirus.
    1. Garcia S., Albaghdadi M.S., Meraj P.M., Schmidt C., Garberich R., Jaffer F.A. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;75(22):2871–2872. - PMC - PubMed